This is good news for big pharma. Transgender medicine presents a huge revenue opportunity.

Monetizing a human by charging them a subscription fee to be who they identify as is a new subscription model that can last a lifetime.

The LTV is huge. The issue is that not many folks identify as trans. If anything, it would be in the interest of Pfizer to encourage more kids to question their identity and transition.